Skip to content

XOMA Corporation XOMA Additional Paid-In Capital

Additional Paid-In Capital at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$397.17M+16.6%
Royalty Pharma logo
Royalty PharmaRPRX
$4.38B+4.1%
Theravance Biopharma logo
Theravance BiopharmaTBPH
$1.16B+0.9%
Innoviva, Inc. logo
Innoviva, Inc.INVA
$884.95M+27.4%
Zymeworks logo
ZymeworksZYME
$107.53M-30.3%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$4.48B+5.4%

Other financials

Income statement

See full
Revenue$12.3M-22.6%
Operating income-$480.0K-108%
Net income$4.5M+88.6%
EPS (diluted)$0.17+183%

Balance sheet

See full
Cash & equivalents$85.6M-5.2%
Total debt$124.7M+9.0%
Total equity$92.9M+9.7%
Total assets$271.9M+27.8%

Cash flow

See full
Operating cash flow$6.1M+178%
CapEx$3.0K-29.4%
Free cash flow-$2.9M+36.0%

Valuation

See full
Market cap$746.04M+159%
Enterprise value$785.17M+152%
P/E22.1×
P/S15.4×+8.7×

Profitability

See full
Operating margin10.2%+5.5pp
Net margin69.6%+64.0pp
FCF margin-320%-118pp

Returns & leverage

See full
Return on equity38.1%+35.2pp
Debt / equity1.3×0.0×
Current ratio3.6×-2.0×

Where this comes from

Reported directly by XOMA Corporation in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: XOMA Corporation’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about XOMA Corporation's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is XOMA Corporation's additional paid-in capital?
XOMA Corporation (XOMA) reported additional paid-in capital of $1.31B in Q1 2026.
How has XOMA Corporation's additional paid-in capital changed year-over-year?
XOMA Corporation's additional paid-in capital decreased by 0.7% year-over-year, from $1.32B to $1.31B.
What is the long-term trend for XOMA Corporation's additional paid-in capital?
Over 5 years (2020 to 2025), XOMA Corporation's additional paid-in capital has grown at a 0.6% compound annual growth rate (CAGR), from $1.27B to $1.31B.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.